UCB, a global biopharmaceutical company, announced data for Bimzelx in active moderate-to-severe hidradenitis suppurativa (HS) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver.
These data from three post hoc analyses of the BE HEARD trials show the potential of Bimzelx to provide durable symptom relief for people living with this challenging dermatological condition.
The three-year data reported for the Be Heard extension trial (Be Heard ext) includes the Bimzelx total patients who completed Week 148 (N=367).
Of those who entered Be Heard ext, the cumulative proportion who were free of acute exacerbation of symptoms (defined as a ≥25% increase in abscess and inflammatory nodule (AN) count versus baseline with an absolute increase in AN count of ≥2) at any scheduled clinic visit up to three years was 86.1% (316/367).
In a separate post hoc analysis, Hidradenitis Suppurativa Clinical Response (HiSCR) response at three years was assessed for patients in the lowest disease duration quartile (<2.38 years since HS diagnosis) with moderate baseline disease severity (as defined by Hurley Stage II) versus highest disease duration quartile (≥10.74 years since HS diagnosis) with severe baseline disease severity (as defined by Hurley Stage III).
At three years, HiSCR90/100 was achieved by 74.1% (43/58)/62.1% (36/58), respectively, in those with the lowest disease duration and moderate baseline HS, versus 51.5% (17/33)/33.3% (11/33), respectively, with the highest disease duration and severe baseline HS.
In a third post hoc analysis, HiSCR response at three years was assessed in subgroups: age (<35 years vs ≥35 years), sex, median disease duration at baseline (<5.02, ≥5.02 years), severity assessed by Hurley Stage (II, III), body mass index (<30 kg/m2, 30–<35 kg/m2, ≥35 kg/m2).
Bimzelx was associated with efficacy improvements in all subgroups, with improvements in clinical response maintained over three years.
These data form part of UCB’s broader presence at the 2026 AAD Annual Meeting, where a total of eleven abstracts will be presented across the Bimzelx portfolio in hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
